Oncology Nurse Edition Current Issue Header

Article

CURRENT ISSUE

August 2012  |  Volume 26 • Number 8

Recent Videos
Adding bortezomib to Isa-Rd triplet therapy enhanced MRD-negative responses in patients with transplant-ineligible multiple myeloma.
Isatuximab plus VRd triplet therapy did not significantly increase toxicity in patients with transplant-ineligible multiple myeloma in the IMROZ trial.
Isatuximab quadruplet therapy for patients with multiple myeloma prolonged progression-free survival when compared with VRd triplet therapy.
Retrospective study data show that patients with inflammatory bowel disease may not require modification of standard radiotherapy for pelvic malignancies.
Prospective trial data may help guide treatment planning for patients with inflammatory bowel disease planning to undergo radiotherapy.
Samantha Shenoy, NP, MSN, suggests that support groups may help comfort patients experiencing adverse effects negatively impacting quality of life.
Related Content
Use of DCISionRT may open new options for tailored treatments among patients with HER2-positive ductal carcinoma in situ.

Biosignature Test May Predict Residual Risk Post-BCS/RT in HER2+ DCIS

Russ Conroy
October 2nd 2024
Article

Use of DCISionRT may open new options for tailored treatments among patients with HER2-positive ductal carcinoma in situ.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

James R. Berenson, MD, FACP
September 30th 2024
Podcast

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Efficacy findings were enhanced when 177Lu-Dotatate was used to treat patients with grade II/III recurrent meningioma.

177Lu-Dotatate Improves PFS in Recurrent Meningioma

Ariana Pelosci
October 1st 2024
Article

Efficacy findings were enhanced when 177Lu-Dotatate was used to treat patients with grade II/III recurrent meningioma.

Investigators of the Gliofocus trial look to set a clinically relevant “benchmark” in the glioblastoma field, according to Nader Sanai, MD.

Advancing Glioblastoma Research Through a Phase 3 Niraparib Trial

Nader Sanai, MD
September 23rd 2024
Podcast

Investigators of the Gliofocus trial look to set a clinically relevant “benchmark” in the glioblastoma field, according to Nader Sanai, MD.

Data from DESTINY-Breast06 support the priority review designation for T-DXd as a treatment for HER2-low or HER2-ultralow breast cancer.

T-DXd Earns FDA Priority Review in Pretreated HER2-Low Breast Cancer

Russ Conroy
October 1st 2024
Article

Data from DESTINY-Breast06 support the priority review designation for T-DXd as a treatment for HER2-low or HER2-ultralow breast cancer.

Starting at the Front Line in Metastatic Pancreatic Cancer As New Options Emerge, How Do You Select and Sequence?

Starting at the Front Line in Metastatic Pancreatic Cancer As New Options Emerge, How Do You Select and Sequence?

Zev A. Wainberg, MD;Tanios S. Bekaii-Saab, MD, FACP;Eileen M. O'Reilly, MD;Shubham Pant, MD
October 1st 2024
Article

Experts in gastrointestinal cancer focus on frontline therapy options for patients with pancreatic cancer.